A new trial has been launched to assess whether ibuprofen could help reduce respiratory failure in patients with severe symptoms of Covid-19.
It is hoped that the special formulation of the cheap anti-inflammatory drug, to be delivered at a certain point in illness among hospital patients, will reduce severe respiratory illness. This could potentially lead to shorter hospital stays and fewer patients needing help in intensive care units (ICU).
Mitul Mehta, professor of neuroimaging and psychopharmacology and director of Centre for Innovative Therapeutics at Kings College London, told the PA news agency: “It’s a trial for patients with Covid-19 disease to see if giving them an anti-inflammatory drug, a specific form of ibuprofen, will reduce the respiratory problems they have.”
He emphasised that the trial was for hospitalised patients and not those who have mild or suspected Covid-19. Participants will be taken from those who are hospitalised, but not so ill that they need intensive care.
“And if we can reduce their symptoms at that stage we have a number of benefits: we could reduce the amount of time that someone spends in hospital, they might recover quicker and go home, that’s obviously a fantastic outcome; we also might be reducing the degree of respiratory distress so that it can be managed in the hospital setting, without needing to go to ICU. And that is a fantastic outcome as well.
Theoretically, this treatment, given at this time, should be beneficial. But this is based on animal studies. It’s based on case reports, we need to do a trial to show that the evidence actually matches what we expect to happen.”
Prof Mehta mentioned that animal studies into acute respiratory distress syndrome – a symptom of Covid-19 disease, shows that around 80% of animals with this condition die, but when they are given this special formulation of ibuprofen the survival rates increase to 80%.
“This is very promising, but of course it is an animal study, so we want to translate that really compelling result into humans,” he said.
The trial is a joint effort between experts from Guy’s and St Thomas’ NHS Foundation Trust, King’s College London and the pharmaceutical organisation the SEEK Group. Half of the patients enrolled in the trial will receive standard care and the other half will receive standard care plus the special ibuprofen formulation.
It is hoped that the way the drug has been formulated will reduce potential gastric side effects linked to ibuprofen.
Professor Matthew Hotopf, director of the NIHR Maudsley Biomedical Research Centre said: “This highly innovative therapeutic approach seeks to rapidly advance a potentially important new treatment. If successful, the global public health value of this trial result would be immense given the low cost and availability of this medicine.”
Scientists in Britain have launched a review to assess ties to the drug and Covid-19.
The Commission on Human Medicines’ expert working group concluded: “There is currently insufficient evidence to establish a link between use of ibuprofen and susceptibility to contracting Covid-19 or the worsening of its symptoms.”